By NewsDesk  @bactiman63 Vaccine company, Valneva, announced Monday positive antibody persistence data twelve months after vaccination with a single dose of its chikungunya vaccine candidate, VLA1553. Following...

By

Immunovaccine Inc., a clinical stage vaccine and immunotherapy company, today announced that three different recombinant protective antigen (rPA) vaccines formulated with its novel DepoVax™ enhancement...